Preissner K T, Zwicker L, Müller-Berghaus G
Biochem J. 1987 Apr 1;243(1):105-11. doi: 10.1042/bj2430105.
S protein, a plasma glycoprotein with Mr 78,000, has been shown to interfere with the heparin-catalysed inhibition of thrombin by antithrombin III. This interaction was further evaluated in the present study. Native human blood was replaced by either radiolabelled antithrombin III or radiolabelled prothrombin in the reaction mixture, which was incubated at 37 degrees C. At various time intervals the serum formed from the incubated blood was withdrawn and analysed by crossed immunoelectrophoresis against anti-(S protein) serum in the second dimension. Increasing quantities of radioactivity originating both from antithrombin III and from thrombin were precipitated in a cathodal shoulder to the S protein peak. This observation indicated the formation of a ternary S protein-thrombin-antithrombin III (STAT) complex in serum. This complex could also be observed by the same technique after incubation of purified thrombin in the presence of antithrombin III and S protein. Complex-formation was independent of the presence of heparin and did not require Ca2+ ions. Owing to the association of S protein with the thrombin-antithrombin III (TAT) complex, the STAT complex assembled in vitro exhibited a higher Mr than the TAT complex as judged by polyacrylamide-gradient-gel electrophoresis in the absence of SDS. Both the serum-originated STAT complex and the STAT complex assembled from purified components sedimented faster than the single components and showed comparable apparent sedimentation coefficients in the range 11-14 S, corresponding to a mean Mr of 350,000. The STAT complex could be detected in serum at a dilution of 1:3200 by a sensitive immuno-radiometric assay employing affinity-purified IgG against S protein. These results indicate that S protein, in addition to its role as a heparin-neutralizing factor, becomes incorporated into the nascent TAT complex or can bind to preformed TAT complex during the clotting process.
S蛋白是一种分子量为78,000的血浆糖蛋白,已被证明可干扰抗凝血酶III对肝素催化的凝血酶抑制作用。本研究进一步评估了这种相互作用。在37℃孵育的反应混合物中,用人源天然血液替换为放射性标记的抗凝血酶III或放射性标记的凝血酶原。在不同时间间隔,取出孵育血液形成的血清,并通过二维交叉免疫电泳对抗(S蛋白)血清进行分析。来自抗凝血酶III和凝血酶的放射性物质数量不断增加,在S蛋白峰的阴极肩部沉淀。这一观察结果表明血清中形成了三元S蛋白-凝血酶-抗凝血酶III(STAT)复合物。在抗凝血酶III和S蛋白存在下孵育纯化的凝血酶后,也可以通过相同技术观察到这种复合物。复合物的形成与肝素的存在无关,也不需要Ca2+离子。由于S蛋白与凝血酶-抗凝血酶III(TAT)复合物结合,在不存在SDS的情况下,通过聚丙烯酰胺梯度凝胶电泳判断,体外组装的STAT复合物比TAT复合物具有更高的分子量。血清来源的STAT复合物和由纯化成分组装的STAT复合物都比单一成分沉降得更快,并且在11-14 S范围内显示出相当的表观沉降系数,对应于平均分子量350,000。通过使用针对S蛋白的亲和纯化IgG的灵敏免疫放射分析,在1:3200的稀释度下可在血清中检测到STAT复合物。这些结果表明,S蛋白除了作为肝素中和因子的作用外,在凝血过程中还会掺入新生的TAT复合物中或与预先形成的TAT复合物结合。